FirstLine

Latest Posts

First Launch of Part III Head-to-Head Scientific Research Knowledge of Ivonescimab versus Pembrolizumab in...

Market

Two Ivonescimab (PD-1/VEGF) Outcomes together with Part 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Remedy for PD-L1 Constructive NSCLC to Be Offered at WCLC...